Fund Holdings — Atlas Venture Life Science Advisors, LLC

Total Portfolio Value
$881.29M
Total Bought
$135.11M
Total Sold
$69.46M
Net Transaction
+$65.65M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q1 2026
▲▼
Q2 2026
▲▼
Change
▲▼
Q1 2026
▲▼
Q2 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Kailera Therapeutics, Inc.05,171,282+5,171,2820113,92312.93%+113,923
Q32 Bio, Inc.(FIXX)2,092,1062,717,106+625,00013,43134,6163.93%+21,185
Disc Medicine, Inc.(IRON)1,513,8751,513,875096,797110,72512.56%+13,928
Sionna Therapeutics, Inc.(SION)2,995,6022,995,6020120,094131,77714.95%+11,683
Korro Bio, Inc.(KRRO)1,137,149962,884-174,26512,87312,6911.44%-182
Dyne Therapeutics, Inc.(DYN)9,130,4656,800,099-2,330,366165,535151,03017.14%-14,505
Kymera Therapeutics, Inc.(KYMR)4,578,0082,847,541-1,730,467381,302326,52837.05%-54,775
Page 1 of 1
Atlas Venture Life Science Advisors, LLC — 13F Holdings — Q2 2026 | TickerTrail